---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-017551"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:20:58.563475+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ginkgo files Zymergen Q3 2022 financials; net loss $75.7M on $2.3M revenue

## Summary
- Zymergen Q3 2022: revenue $2.3M, net loss $75.7M, operating loss $75.3M.
- Nine-month 2022: revenue $9.7M, net loss $264.3M, operating loss $245.1M.
- Cash $153.4M at Sep 30, 2022, down from $386.1M at Dec 31, 2021.
- Goodwill impairment charge of $40.6M recorded during 2022.
- Going-concern doubt that existed at June 30, 2022 alleviated by Oct 19, 2022 merger.

## SEC filing metadata
- accession: 0001193125-23-017551
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/0001193125-23-017551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/d443681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-017551
- JSON: https://secwatch.observer/filing/0001193125-23-017551.json
- Plain text: https://secwatch.observer/filing/0001193125-23-017551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.